Literature DB >> 22112390

Low levels of high-density lipoproteins cholesterol are independently associated with acute coronary heart disease in patients hospitalized for chest pain.

Alberto Cordero1, José Moreno-Arribas, Vicente Bertomeu-González, Pilar Agudo, Beatriz Miralles, M Dolores Masiá, Ramón López-Palop, Vicente Bertomeu-Martínez.   

Abstract

INTRODUCTION AND
OBJECTIVES: The role of high-density lipoproteins in the context of acute chest pain has not been well characterized. The objective of this study was to determine the relative contribution of lipid profile to the risk of acute coronary syndrome in patients admitted to a cardiology ward for chest pain.
METHODS: We included all consecutive admissions in a single cardiology department over a period of 10 months and 1-year follow-up was performed.
RESULTS: In total, 959 patients were included: 457 (47.7%) were diagnosed with non-ischemic chest pain, 355 (37%) with non-ST-elevation acute coronary syndrome, and 147 (15.3%) with ST-elevation acute coronary syndrome. Prevalence of high-density lipoproteins <40 mg/dL was 54.6%, and was higher in patients with acute coronary syndrome (69.4% vs 30.6%; P<.01). The prevalence of acute coronary syndrome increased with reductions in mean high-density lipoproteins. Age, active smoking, diabetes, fasting glucose >100 mg/dL, and high-density lipoproteins <40 mg/dL were independently associated with acute coronary syndrome, and low high-density lipoproteins was the main associated factor (odds ratio, 4.11; 95% confidence interval, 2.87-5.96). Survival analysis determined that, compared with non-ischemic chest pain, the presence of acute coronary syndrome was associated with significantly greater risk of all-cause and cardiovascular mortality.
CONCLUSIONS: Low levels of high-density lipoproteins cholesterol (≤40 mg/dL) were independently associated with a diagnosis of acute coronary syndrome in patients hospitalized for chest pain, with an inverse relationship between lower levels of high-density lipoproteins and prevalence of acute coronary syndrome. Copyright Â
© 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112390     DOI: 10.1016/j.recesp.2011.07.022

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  4 in total

1.  Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies.

Authors:  Amal F Alshammary; Khalid Khalaf Alharbi; Naif Jameel Alshehri; Vishal Vennu; Imran Ali Khan
Journal:  Int J Environ Res Public Health       Date:  2021-02-11       Impact factor: 3.390

2.  Analysis of the APOB Gene and Apolipoprotein B Serum Levels in a Mexican Population with Acute Coronary Syndrome: Association with the Single Nucleotide Variants rs1469513, rs673548, rs676210, and rs1042034.

Authors:  Maricela Aceves-Ramírez; Yeminia Valle; Fidel Casillas-Muñoz; Diana Emilia Martínez-Fernández; Brenda Parra-Reyna; Víctor Arturo López-Moreno; Héctor Enrique Flores-Salinas; Emmanuel Valdés-Alvarado; José Francisco Muñoz-Valle; Texali García-Garduño; Jorge Ramón Padilla-Gutiérrez
Journal:  Genet Res (Camb)       Date:  2022-03-31       Impact factor: 1.588

Review 3.  Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain.

Authors:  Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

Review 4.  Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.

Authors:  Diego Estrada-Luna; María Araceli Ortiz-Rodriguez; Lizett Medina-Briseño; Elizabeth Carreón-Torres; Jeannett Alejandra Izquierdo-Vega; Ashutosh Sharma; Juan Carlos Cancino-Díaz; Oscar Pérez-Méndez; Helen Belefant-Miller; Gabriel Betanzos-Cabrera
Journal:  Molecules       Date:  2018-10-23       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.